We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Japanese company refuses to rule out possibility treatment contributed to brain bleeds
Cepi releases blueprint to move three times faster against a new virus than during Covid-19 pandemic
The early death of an Alzheimer’s patient taking part in lecanemab trials sent shares down
Results from UK-wide trials on anticoagulant Apixaban set to change protocols around the world
Addenbrooke’s seeks to tackle problems facing the health service with both low and high-tech advances
Economic and social costs are climbing but Beijing has failed to offer a way out of endless lockdowns
Rising cases in Guangzhou indicate a widening gap between official guidance and reality
Medicines are often given for viral infections such as flu, for which they are useless, but can cause side effects
Plan abandoned almost two years after initial approval in UK and Europe
Could long Covid be the world’s next big workplace health crisis?
Ending of pharma group’s IP truce spells fight for future of mRNA technology
Legal, societal and financial barriers block treatments that can reduce risk of overdose
Fall from €3.2bn in the third quarter of 2021 to €1.8bn
Jab maker ties weaker revenue outlook to delivery delays and manufacturing issues
Market rallies on hopes of looser coronavirus lockdown measures and travel restrictions
US drugmaker’s coronavirus vaccine has almost doubled in price since its launch in 2020
Downing Street internal communications and cabinet minutes requested during probe’s second phase
Despite pledges to learn the lessons of Covid-19, caution is already waning. Plus: crisis turned a spotlight on healthcare services; climate change and urbanisation drive rise in ‘zoonotic’ illnesses; return of polio to US highlights impact of anti-vax campaigners
This is how the world can get faster and smarter in its ability to respond to outbreaks of new infectious diseases
Lack of fair access is ‘one of the biggest chinks in our armour’
Inquiry launched into whether study that created artificial form of disease should have gone through more checks
The head of the UK’s vaccine procurement tells the inside story of the risks, criticism and political interference she faced
Swiss pharma group says demand for coronavirus tests dropped as severity of virus ebbed
Pharmaceutical companies hunt for new revenue streams as coronavirus becomes endemic
Many countries had partisan divides on Covid vaccination, but they were more lethal in the US than anywhere else
International Edition
-50fb56c8-7dba-40d5-8503-10cacf20b6d8.jpeg?source=next&fit=scale-down&dpr=2&width=240)
